Bioartificial Kidneys

被引:24
作者
Corridon P.R. [1 ,2 ,3 ]
Ko I.K. [1 ]
Yoo J.J. [1 ]
Atala A. [1 ]
机构
[1] Wake Forest Institute for Regenerative Medicine, Medical Center Boulevard, Winston-Salem, 27157-1083, NC
[2] Department of Physiology & Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC
[3] Department of Craniofacial Biology, University of Colorado, Anschutz Medical Campus, Aurora, CO
关键词
Bioengineering; Bioratificial kidney; Cell therapy and gene therapy; Dialysis; Regenerative medicine;
D O I
10.1007/s40778-017-0079-3
中图分类号
学科分类号
摘要
Purpose of Review: Historically, there have been many advances in the ways in which we treat kidney diseases. In particular, hemodialysis has set the standard for treatment since the early 1960s and continues today as the most common form of treatment for acute, chronic, and end-stage conditions. However, the rising global prevalence of kidney diseases and our limited understanding of their etiologies have placed significant burdens on current clinical management regimens. This has resulted in a desperate need to improve the ways in which we treat the underlying and ensuing causes of kidney diseases for those who are unable to receive transplants. Recent Findings: One way of possibly addressing these issues is through the use of improved bioartificial kidneys. Bioartificial kidneys provide an extension to conventional artificial kidneys and dialysis systems, by incorporating aspects of living cellular and tissue function, in an attempt to better mimic normal kidneys. Recent advancements in genomic, cellular, and tissue engineering technologies are facilitating the improved design of these systems. Summary: In this review, we outline various research efforts that have focused on the development of regenerated organs, implantable constructs, and whole bioengineered kidneys, as well as the transitions from conventional dialysis to these novel alternatives. As a result, we envision that these pioneering efforts can one day produce bioartificial renal technologies that can either perform or reintroduce essential function, and thus provide practical options to treat and potentially prevent kidney diseases. © 2017, Springer International Publishing AG.
引用
收藏
页码:68 / 76
页数:8
相关论文
共 59 条
  • [1] Stevens L.A., Viswanathan G., Weiner D.E., CKD and ESRD in the elderly: current prevalence, future projections, and clinical significance, Adv Chronic Kidney Dis, 17, 4, pp. 293-301, (2010)
  • [2] Ojo A., Addressing the global burden of chronic kidney disease through clinical and translational research, Trans Am Clin Climatol Assoc, 125, pp. 229-246, (2014)
  • [3] Hunter D.J., Reddy K.S., Noncommunicable diseases, N Engl J Med, 369, 14, pp. 1336-1343, (2013)
  • [4] Abecassis M., Bartlett S.T., Collins A.J., Davis C.L., Delmonico F.L., Friedewald J.J., Et al., Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) conference, Clin J Am Soc Nephrol CJASN, 3, 2, pp. 471-480, (2008)
  • [5] Rosen L., Vining A.R., Weimer D.L., Addressing the shortage of kidneys for transplantation: purchase and allocation through chain auctions, J Health Polit Policy Law, 36, 4, pp. 717-755, (2011)
  • [6] Mallappallil M., Friedman E.A., Delano B.G., McFarlane S.I., Salifu M.O., Chronic kidney disease in the elderly: evaluation and management, Clin Pract Lond Engl, 11, 5, pp. 525-535, (2014)
  • [7] Chapman J.R., What are the key challenges we face in kidney transplantation today?, Transplant Res, 2, 1, pp. 1-7, (2013)
  • [8] Anderson S., Halter J.B., Hazzard W.R., Himmelfarb J., Horne F.M., Kaysen G.A., Et al., Prediction, progression, and outcomes of chronic kidney disease in older adults, J Am Soc Nephrol, 20, 6, pp. 1199-1209, (2009)
  • [9] Hartman M, Washington B, Catlin A, Team the NHEA. National Health Spending: Faster Growth In 2015 As Coverage Expands And Utilization Increases. Health Aff (Millwood), 2016 Dec 2
  • [10] 10.1377/hlthaff, (2016)